NA therapy

Phase 3Small molecule

GSK

NA therapy is one of 50 small molecule programs targeting Chronic Hepatitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic HepatitisActive, not recruiting

Chronic Hepatitis BRecruiting

Chronic HepatitisPhase 3

Active, not recruiting

Chronic Hepatitis BPhase 2

Recruiting

Competition

Competitive Landscape

71 competitors in Chronic Hepatitis

#DrugCompanyPhaseTrials

PEG-Intron

Merck & Co.

Phase 3

43 2

Emtriva

Gilead

Approved

3 3

Jardiance

Boehringer Ingelheim

Approved

1 4

PEGASYS

Ppharmaand GmbH

Approved

24 5

Opdivo

Bristol-Myers Squibb

Phase 2

2 6

Pegylated Interferon Alfa

Merck & Co.

Phase 3

4 7

AHB-137

AAusper Biopharma Co., Ltd.

Phase 3

3 8

Hydronidone

BBeijing Continent Pharmaceutical Co, Ltd.

Phase 3

2 9

Azvudine

HHenan Genuine Biotech Co., Ltd.

Phase 3

1 10

Tenofovir DF

Gilead

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Recruiting

Chronic Hepatitis B

NCT07137910

Q3 2027

Phase 3Active, not recruiting

Chronic Hepatitis

NCT07246889

Clinical

Trials by Indication[1]

Chronic Hepatitis2 trials

Study of Sequential GSK3228836 and Peginterferon Treatment in Participants With Chronic Hepatitis B (CHB)

Completed· GSK logo

GSK·Phase 2·NCT04676724·108 enrolled

Study of AHB-137 in Participants With Chronic Hepatitis B (CHB) Treated With Nucleos(t)Ide Analogues (NAs)(AUSHINE)

Active, not recruiting·AAusper Biopharma Co., Ltd.·Phase 3·NCT07246889·577 enrolled

Chronic Hepatitis b1 trial

An Open-Label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Low-HBsAg Chronic Hepatitis B

Recruiting·AAusper Biopharma Co., Ltd.·Phase 2·NCT07137910·200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for NA therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NA therapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NA therapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: GSK

NA therapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q3 2027

Trials by Indication[1]

Chronic Hepatitis2 trials

Chronic Hepatitis b1 trial

References

Drug Info

Quick Facts

Related News